Coegin Pharma AB (NGM: COEGIN)

Market Cap	79.51M
Revenue (ttm)	n/a
Net Income (ttm)	-26.01M
Shares Out	20.39M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,419
Open	n/a
Previous Close	3.950
Day's Range	n/a
52-Week Range	2.580 - 8.300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2025

About Coegin Pharma AB

Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascula...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 2
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: COEGIN